Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh; Jim Zhang; Andra Zamurs; Jacquelyn Fleegle; William R. Thelin; Ray A. Caldwell; Juan R. Sabater; William M. Abraham; Mark Donowitz; Boyoung Cha; Kevin B. Johnson; Judith A. St. George; M. Ross Johnson; Richard C. Boucher

doi:10.1124/jpet.107.130443

Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Jim Zhang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Ray A. Caldwell, Juan R. Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, Judith A. St. George, M. Ross Johnson and Richard C. Boucher

Journal of Pharmacology and Experimental Therapeutics April 2008, 325 (1) 77-88; DOI: https://doi.org/10.1124/jpet.107.130443

Andrew J. Hirsh

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jim Zhang

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andra Zamurs

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacquelyn Fleegle

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William R. Thelin

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ray A. Caldwell

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Juan R. Sabater

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William M. Abraham

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark Donowitz

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Boyoung Cha

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kevin B. Johnson

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Judith A. St. George

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

M. Ross Johnson

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard C. Boucher

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 379, Issue 3

1 Dec 2021

Table of Contents
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung …

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Journal of Pharmacology and Experimental Therapeutics April 1, 2008, 325 (1) 77-88; DOI: https://doi.org/10.1124/jpet.107.130443

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Journal of Pharmacology and Experimental Therapeutics April 1, 2008, 325 (1) 77-88; DOI: https://doi.org/10.1124/jpet.107.130443

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Plain text

Vertical Tabs

Jump to comment:

In this issue

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Citation Manager Formats

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals